Datamonitor’s OTC Pharmaceuticals - Top 5 Emerging Markets Industry Guide is an essential resource for top-level data and analysis covering the OTC Pharmaceuticals industry in each of the Top 5 Emerging markets (Brazil, China, India, Mexico and South Africa). The report includes easily comparable data on market value, volume, segmentation and market share, plus full five year market forecasts. It examines future problems, innovations and potential growth areas within the market.
Scope of the Report
* Contains an executive summary and data on value, volume and segmentation
* Provides textual analysis of the industry’s prospects, competitive landscape and profiles of the leading companies
* Incorporates in-depth five forces competitive environment analysis and scorecards
* Compares data from Brazil, China, India, Mexico and South Africa, alongside individual chapters on each country. .
* Includes a five-year forecast of the industry
Highlights
The Top 5 Emerging countries contributed $17658.8 million to the global OTC Pharmaceuticals industry in 2009, with a CAGR of 7% between 2005 and 2009
China is the leading country among the Top 5 emerging nations, with market revenues of $9,811. million in 2009.
The China is expected to lead the otc pharmaceuticals industry in the Top five emerging nations, with a value of $13,449.9 in 2014
Why you should buy this report
* Spot future trends and developments
* Inform your business decisions
* Add weight to presentations and marketing materials
* Save time carrying out entry-level research
Market Definition
The OTC pharmaceuticals market consists of the retail sale of traditional medicines, cough and cold preparations (tablets, mixtures, lozenges, topical remedies, inhalers), vitamins and minerals (multi-vitamins, single minerals, single vitamins, tonics, cod liver oil), indigestion preparations (tablets, powders, mixtures), analgesics (Paracetamol, Ibuprofen, Aspirinand other analgesics), and medicated skin products (anti-bacteria’s, acne treatments, anti-fungal, disinfectants and other), topical OTC medicines (anesthetic products, anti-itch products, antibiotic creams/gels), plasters & bandages (adhesive bandages/plasters, first aid tape, gauze pads/rolled gauze, liquid bandages and other tape or bandage), first aid kits and other (anti-smoking aids, rectal medications, eye/ear drops, sleeping aids, and motion sickness).
ABOUT DATAMONITOR 2
INTRODUCTION 15
What is this report about? 15
Who is the target reader? 15
How to use this report 15
Definitions 15
TOP 5 EMERGING COUNTRIES OTC PHARMACEUTICALS OUTLOOK 16
OTC PHARMACEUTICALS IN SOUTH AFRICA 22
Market overview 22
Market value 23
Market segmentation I 24
Market share 26
Five forces analysis 27
Leading companies 35
Market distribution 43
Market Forecasts 44
Macroeconomic indicators 46
OTC PHARMACEUTICALS IN BRAZIL 48
Market overview 48
Market value 49
Market segmentation I 50
Market segmentation II 51
Market share 52
Five forces analysis 53
Leading companies 62
Market distribution 80
Market Forecasts 81
Macroeconomic indicators 83
OTC PHARMACEUTICALS IN CHINA 85
Market overview 85
Market value 86
Market segmentation I 87
Market segmentation II 88
Market share 89
Five forces analysis 90
Leading companies 98
Market distribution 110
Market Forecasts 111
Macroeconomic indicators 113
OTC PHARMACEUTICALS IN INDIA 115
Market overview 115
Market value 116
Market segmentation I 117
Market segmentation II 118
Market share 119
Five forces analysis 120
Leading companies 128
Market distribution 149
Market Forecasts 150
Macroeconomic indicators 152
OTC PHARMACEUTICALS IN MEXICO 154
Market overview 154
Market value 155
Market segmentation I 156
Market segmentation II 157
Market share 158
Five forces analysis 159
Leading companies 168
Market distribution 187
Market Forecasts 188
Macroeconomic indicators 190
APPENDIX 192
Data Research Methodology 192
LIST OF TABLES
Table 1: Top 5 emerging countries otc pharmaceuticals industry, revenue ($m), 2005–14 17
Table 2: Top 5 emerging countries otc pharmaceuticals industry, revenue ($m), 2005–09 19
Table 3: Top 5 emerging countries otc pharmaceuticals industry forecast, revenue ($m), 2009–14 21
Table 4: South Africa otc pharmaceuticals market value: $ million, 2005–09 23
Table 5: South Africa otc pharmaceuticals market segmentation I:% share, by value, 2009 24
Table 6: South Africa otc pharmaceuticals market share: % share, by value, 2009 26
Table 7: Pharma Natura (Pty) Ltd: key facts 35
Table 8: Weleda Group: key facts 36
Table 9: Johnson & Johnson: key facts 37
Table 10: Johnson & Johnson: key financials ($) 40
Table 11: Johnson & Johnson: key financial ratios 41
Table 12: South Africa otc pharmaceuticals market distribution: % share, by value, 2009 43
Table 13: South Africa OTC pharmaceuticals market value forecast: $ million, 2009–14 44
Table 14: South Africa size of population (million), 2005–09 46
Table 15: South Africa gdp (constant 2000 prices, $ billion), 2005–09 46
Table 16: South Africa gdp (current prices, $ billion), 2005–09 46
Table 17: South Africa inflation, 2005–09 47
Table 18: South Africa consumer price index (absolute), 2005–09 47
Table 19: South Africa exchange rate, 2005–09 47
Table 20: Brazil otc pharmaceuticals market value: $ million, 2005–09 49
Table 21: Brazil otc pharmaceuticals market segmentation I:% share, by value, 2009 50
Table 22: Brazil otc pharmaceuticals market segmentation II: % share, by value, 2009 51
Table 23: Brazil otc pharmaceuticals market share: % share, by value, 2009 52
Table 24: Johnson & Johnson: key facts 62
Table 25: Johnson & Johnson: key financials ($) 65
Table 26: Johnson & Johnson: key financial ratios 66
Table 27: Sanofi-Aventis: key facts 68
Table 28: Sanofi-Aventis: key financials ($) 71
Table 29: Sanofi-Aventis: key financials (€) 71
Table 30: Sanofi-Aventis: key financial ratios 72
Table 31: Abbott Laboratories: key facts 74
Table 32: Abbott Laboratories: key financials ($) 77
Table 33: Abbott Laboratories: key financial ratios 77
Table 34: Brazil otc pharmaceuticals market distribution: % share, by value, 2009 80
Table 35: Brazil OTC pharmaceuticals market value forecast: $ million, 2009–14 81
Table 36: Brazil size of population (million), 2005–09 83
Table 37: Brazil gdp (constant 2000 prices, $ billion), 2005–09 83
Table 38: Brazil gdp (current prices, $ billion), 2005–09 83
Table 39: Brazil inflation, 2005–09 84
Table 40: Brazil consumer price index (absolute), 2005–09 84
Table 41: Brazil exchange rate, 2005–09 84
Table 42: China otc pharmaceuticals market value: $ million, 2005–09 86
Table 43: China otc pharmaceuticals market segmentation I:% share, by value, 2009 87
Table 44: China otc pharmaceuticals market segmentation II: % share, by value, 2009 88
Table 45: China otc pharmaceuticals market share: % share, by value, 2009 89
Table 46: Johnson & Johnson: key facts 98
Table 47: Johnson & Johnson: key financials ($) 101
Table 48: Johnson & Johnson: key financial ratios 102
Table 49: Novartis AG: key facts 104
Table 50: Novartis AG: key financials ($) 106
Table 51: Novartis AG: key financial ratios 107
Table 52: Chengdu Rosun Antiseptic Pharmaceutical Co., Ltd: key facts 109
Table 53: China otc pharmaceuticals market distribution: % share, by value, 2009 110
Table 54: China OTC pharmaceuticals market value forecast: $ million, 2009–14 111
Table 55: China size of population (million), 2005–09 113
Table 56: China gdp (constant 2000 prices, $ billion), 2005–09 113
Table 57: China gdp (current prices, $ billion), 2005–09 113
Table 58: China inflation, 2005–09 114
Table 59: China consumer price index (absolute), 2005–09 114
Table 60: China exchange rate, 2005–09 114
Table 61: India otc pharmaceuticals market value: $ million, 2005–09 116
Table 62: India otc pharmaceuticals market segmentation I:% share, by value, 2009 117
Table 63: India otc pharmaceuticals market segmentation II: % share, by value, 2009 118
Table 64: India otc pharmaceuticals market share: % share, by value, 2009 119
Table 65: Cipla Ltd: key facts 128
Table 66: Cipla Ltd: key financials ($) 132
Table 67: Cipla Ltd: key financials (Rs.) 132
Table 68: Cipla Ltd: key financial ratios 132
Table 69: Johnson & Johnson: key facts 135
Table 70: Johnson & Johnson: key financials ($) 139
Table 71: Johnson & Johnson: key financial ratios 139
Table 72: GlaxoSmithKline Plc: key facts 142
Table 73: GlaxoSmithKline Plc: key financials ($) 146
Table 74: GlaxoSmithKline Plc: key financials (£) 146
Table 75: GlaxoSmithKline Plc: key financial ratios 147
Table 76: India otc pharmaceuticals market distribution: % share, by value, 2009 149
Table 77: India OTC pharmaceuticals market value forecast: $ million, 2009–14 150
Table 78: India size of population (million), 2005–09 152
Table 79: India gdp (constant 2000 prices, $ billion), 2005–09 152
Table 80: India gdp (current prices, $ billion), 2005–09 152
Table 81: India inflation, 2005–09 153
Table 82: India consumer price index (absolute), 2005–09 153
Table 83: India exchange rate, 2005–09 153
Table 84: Mexico otc pharmaceuticals market value: $ million, 2005–09 155
Table 85: Mexico otc pharmaceuticals market segmentation I:% share, by value, 2009 156
Table 86: Mexico otc pharmaceuticals market segmentation II: % share, by value, 2009 157
Table 87: Mexico otc pharmaceuticals market share: % share, by value, 2009 158
Table 88: Bayer AG: key facts 168
Table 89: Bayer AG: key financials ($) 172
Table 90: Bayer AG: key financials (€) 172
Table 91: Bayer AG: key financial ratios 172
Table 92: Johnson & Johnson: key facts 175
Table 93: Johnson & Johnson: key financials ($) 178
Table 94: Johnson & Johnson: key financial ratios 178
Table 95: Boehringer Ingelheim GmbH: key facts 181
Table 96: Boehringer Ingelheim GmbH: key financials ($) 184
Table 97: Boehringer Ingelheim GmbH: key financials (€) 184
Table 98: Boehringer Ingelheim GmbH: key financial ratios 185
Table 99: Mexico otc pharmaceuticals market distribution: % share, by value, 2009 187
Table 100: Mexico OTC pharmaceuticals market value forecast: $ million, 2009–14 188
Table 101: Mexico size of population (million), 2005–09 190
Table 102: Mexico gdp (constant 2000 prices, $ billion), 2005–09 190
Table 103: Mexico gdp (current prices, $ billion), 2005–09 190
Table 104: Mexico inflation, 2005–09 191
Table 105: Mexico consumer price index (absolute), 2005–09 191
Table 106: Mexico exchange rate, 2005–09 191
LIST OF FIGURES
Figure 1: Top 5 emerging countries otc pharmaceuticals industry, revenue ($m), 2005–14 16
Figure 2: Top 5 emerging countries otc pharmaceuticals industry, revenue ($m), 2005–09 18
Figure 3: Top 5 emerging countries otc pharmaceuticals industry forecast, revenue ($m), 2009–14 20
Figure 4: South Africa otc pharmaceuticals market value: $ million, 2005–09 23
Figure 5: South Africa otc pharmaceuticals market segmentation I:% share, by value, 2009 25
Figure 6: South Africa otc pharmaceuticals market share: % share, by value, 2009 26
Figure 7: Forces driving competition in the otc pharmaceuticals market in South Africa, 2009 27
Figure 8: Drivers of buyer power in the otc pharmaceuticals market in South Africa, 2009 29
Figure 9: Drivers of supplier power in the otc pharmaceuticals market in South Africa, 2009 30
Figure 10: Factors influencing the likelihood of new entrants in the otc pharmaceuticals market in South Africa, 2009 31
Figure 11: Factors influencing the threat of substitutes in the otc pharmaceuticals market in South Africa, 2009 33
Figure 12: Drivers of degree of rivalry in the otc pharmaceuticals market in South Africa, 2009 34
Figure 13: Johnson & Johnson: revenues & profitability 41
Figure 14: Johnson & Johnson: assets & liabilities 42
Figure 15: South Africa otc pharmaceuticals market distribution: % share, by value, 2009 43
Figure 16: South Africa OTC pharmaceuticals market value forecast: $ million, 2009–14 45
Figure 17: Brazil otc pharmaceuticals market value: $ million, 2005–09 49
Figure 18: Brazil otc pharmaceuticals market segmentation I:% share, by value, 2009 50
Figure 19: Brazil otc pharmaceuticals market segmentation II: % share, by value, 2009 51
Figure 20: Brazil otc pharmaceuticals market share: % share, by value, 2009 52
Figure 21: Forces driving competition in the otc pharmaceuticals market in Brazil, 2009 53
Figure 22: Drivers of buyer power in the otc pharmaceuticals market in Brazil, 2009 55
Figure 23: Drivers of supplier power in the otc pharmaceuticals market in Brazil, 2009 56
Figure 24: Factors influencing the likelihood of new entrants in the otc pharmaceuticals market in Brazil, 2009 57
Figure 25: Factors influencing the threat of substitutes in the otc pharmaceuticals market in Brazil, 2009 59
Figure 26: Drivers of degree of rivalry in the otc pharmaceuticals market in Brazil, 2009 60
Figure 27: Johnson & Johnson: revenues & profitability 66
Figure 28: Johnson & Johnson: assets & liabilities 67
Figure 29: Sanofi-Aventis: revenues & profitability 72
Figure 30: Sanofi-Aventis: assets & liabilities 73
Figure 31: Abbott Laboratories: revenues & profitability 78
Figure 32: Abbott Laboratories: assets & liabilities 79
Figure 33: Brazil otc pharmaceuticals market distribution: % share, by value, 2009 80
Figure 34: Brazil OTC pharmaceuticals market value forecast: $ million, 2009–14 82
Figure 35: China otc pharmaceuticals market value: $ million, 2005–09 86
Figure 36: China otc pharmaceuticals market segmentation I:% share, by value, 2009 87
Figure 37: China otc pharmaceuticals market segmentation II: % share, by value, 2009 88
Figure 38: China otc pharmaceuticals market share: % share, by value, 2009 89
Figure 39: Forces driving competition in the otc pharmaceuticals market in China, 2009 90
Figure 40: Drivers of buyer power in the otc pharmaceuticals market in China, 2009 92
Figure 41: Drivers of supplier power in the otc pharmaceuticals market in China, 2009 93
Figure 42: Factors influencing the likelihood of new entrants in the otc pharmaceuticals market in China, 2009 94
Figure 43: Factors influencing the threat of substitutes in the otc pharmaceuticals market in China, 2009 96
Figure 44: Drivers of degree of rivalry in the otc pharmaceuticals market in China, 2009 97
Figure 45: Johnson & Johnson: revenues & profitability 102
Figure 46: Johnson & Johnson: assets & liabilities 103
Figure 47: Novartis AG: revenues & profitability 107
Figure 48: Novartis AG: assets & liabilities 108
Figure 49: China otc pharmaceuticals market distribution: % share, by value, 2009 110
Figure 50: China OTC pharmaceuticals market value forecast: $ million, 2009–14 112
Figure 51: India otc pharmaceuticals market value: $ million, 2005–09 116
Figure 52: India otc pharmaceuticals market segmentation I:% share, by value, 2009 117
Figure 53: India otc pharmaceuticals market segmentation II: % share, by value, 2009 118
Figure 54: India otc pharmaceuticals market share: % share, by value, 2009 119
Figure 55: Forces driving competition in the otc pharmaceuticals market in India, 2009 120
Figure 56: Drivers of buyer power in the otc pharmaceuticals market in India, 2009 122
Figure 57: Drivers of supplier power in the otc pharmaceuticals market in India, 2009 123
Figure 58: Factors influencing the likelihood of new entrants in the otc pharmaceuticals market in India, 2009 124
Figure 59: Factors influencing the threat of substitutes in the otc pharmaceuticals market in India, 2009 126
Figure 60: Drivers of degree of rivalry in the otc pharmaceuticals market in India, 2009 127
Figure 61: Cipla Ltd: revenues & profitability 133
Figure 62: Cipla Ltd: assets & liabilities 134
Figure 63: Johnson & Johnson: revenues & profitability 140
Figure 64: Johnson & Johnson: assets & liabilities 141
Figure 65: GlaxoSmithKline Plc: revenues & profitability 147
Figure 66: GlaxoSmithKline Plc: assets & liabilities 148
Figure 67: India otc pharmaceuticals market distribution: % share, by value, 2009 149
Figure 68: India OTC pharmaceuticals market value forecast: $ million, 2009–14 151
Figure 69: Mexico otc pharmaceuticals market value: $ million, 2005–09 155
Figure 70: Mexico otc pharmaceuticals market segmentation I:% share, by value, 2009 156
Figure 71: Mexico otc pharmaceuticals market segmentation II: % share, by value, 2009 157
Figure 72: Mexico otc pharmaceuticals market share: % share, by value, 2009 158
Figure 73: Forces driving competition in the otc pharmaceuticals market in Mexico, 2009 159
Figure 74: Drivers of buyer power in the otc pharmaceuticals market in Mexico, 2009 161
Figure 75: Drivers of supplier power in the otc pharmaceuticals market in Mexico, 2009 162
Figure 76: Factors influencing the likelihood of new entrants in the otc pharmaceuticals market in Mexico, 2009 163
Figure 77: Factors influencing the threat of substitutes in the otc pharmaceuticals market in Mexico, 2009 165
Figure 78: Drivers of degree of rivalry in the otc pharmaceuticals market in Mexico, 2009 166
Figure 79: Bayer AG: revenues & profitability 173
Figure 80: Bayer AG: assets & liabilities 174
Figure 81: Johnson & Johnson: revenues & profitability 179
Figure 82: Johnson & Johnson: assets & liabilities 180
Figure 83: Boehringer Ingelheim GmbH: revenues & profitability 185
Figure 84: Boehringer Ingelheim GmbH: assets & liabilities 186
Figure 85: Mexico otc pharmaceuticals market distribution: % share, by value, 2009 187
Figure 86: Mexico OTC pharmaceuticals market value forecast: $ million, 2009–14 189
Other selected research from the 'OTC' category:
Personal Hygiene/ Personal Care: Global Industry Guide
Retail Clinics and the In-Store Healthcare Market 2009: Bright Spot in the Current Economy?